High SLC20A1 Expression Indicates Poor Prognosis in Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Solute carrier family 20 member 1 (SLC20A1) high expression correlates with poor outcomes in breast cancer subtypes treated with endocrine therapy and radiotherapy.
• The prognostic role of SLC20A1 in prostate cancer remains unclear.

Purpose of the Study:

• To investigate the association between SLC20A1 expression and clinical outcomes in prostate cancer.
• To evaluate the impact of endocrine therapy and radiotherapy on patients with high SLC20A1 expression.

Main Methods:

• Analysis of open-source datasets including The Cancer Genome Atlas (TCGA) prostate and PanCancer Atlas.
• Assessment of SLC20A1 expression in prostate cancer versus normal prostate tissue.
• Kaplan-Meier and Cox regression analyses for survival and treatment effect evaluation.

Main Results:

• SLC20A1 expression is significantly higher in prostate cancer tissues compared to normal tissues.
• Elevated SLC20A1 expression is a predictor of poor disease-free and progression-free survival.
• High SLC20A1 expression showed a trend towards poor outcomes after radiotherapy, but not after endocrine therapy.

Conclusions:

• SLC20A1 demonstrates potential as a prognostic biomarker for prostate cancer.
• Endocrine therapy may be the preferred treatment modality for prostate cancer patients with high SLC20A1 expression.